(NASDAQ: UBX) Unity Biotechnology's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 64.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.48%.
Unity Biotechnology's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast UBX's revenue for 2026 to be $333,979,411, with the lowest UBX revenue forecast at $333,979,411, and the highest UBX revenue forecast at $333,979,411. On average, 1 Wall Street analysts forecast UBX's revenue for 2027 to be $704,055,586, with the lowest UBX revenue forecast at $704,055,586, and the highest UBX revenue forecast at $704,055,586.
In 2028, UBX is forecast to generate $1,064,517,202 in revenue, with the lowest revenue forecast at $1,064,517,202 and the highest revenue forecast at $1,064,517,202.